[The effects of mepartricin on the symptomatology of prostatic hypertrophy--double-blind controlled trial].
Seventy one patients were treated with mepartricin or placebo in three urological centres for a mean duration of 102 days (extremes: 60 and 142 days). An analysis of the results was carried out for 34 patients in the placebo group and 36 patients in the mepartricin group. The results indicate a significant improvement in both the placebo group and the mepartricin group. The irritative and obstructive symptoms are improved in the active treatment group with a response rate of the order of 70%, compared to approx. 45% in the placebo group. An improvement of the values on the flow meter, though not statistically significant, is observed following treatment with mepartricin, compared to the placebo group. There were no significant differences in the evolution of the prostate gland volume, determined by ultrasound in the placebo group and the active treatment group. Side-effects were minor and only one patient reported epigastric pain.
Vanden Bossche
M
M
Service d'Urologié, Hôpital Universitaire Erasme, Bruxelles.
Abi Aad
A
A
Vandendris
M
M
Van Cangh
P
P
Schulman
C
C
D000368:Aged; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008613:Mepartricin / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
D008613:Mepartricin
Etude de l'effect de la mépartricine sur la symptomatologie de l'hypertrophie prostatique--expérimentation contrôlée en double aveugle.